<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606109</url>
  </required_header>
  <id_info>
    <org_study_id>18-00535</org_study_id>
    <nct_id>NCT03606109</nct_id>
  </id_info>
  <brief_title>Reducing Hemarthrosis in Tibial Tubercle Osteotomy by the Administration of Intravenous Tranexamic Acid</brief_title>
  <official_title>Reducing Hemarthrosis in Tibial Tubercle Osteotomy by the Administration of Intravenous Tranexamic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the proposed study is to evaluate the effects of administering intravenous&#xD;
      tranexamic acid (TXA) to patients undergoing tibial tubercle osteotomy (TTO) to minimize&#xD;
      hemarthrosis within the knee joint and post-operative pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not Provided&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 26, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative hemarthrosis</measure>
    <time_frame>Day 1</time_frame>
    <description>measured by documenting peri-operative blood loss and assessing the operative knee at the first post-operative visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative opioid consumption</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative opioid consumption</measure>
    <time_frame>Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative opioid consumption</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative patient reported pain score on the visual analog scale</measure>
    <time_frame>Day 1</time_frame>
    <description>The visual analog scale (VAS) is a validated, subjective measure for pain. Scores range from 0-10 (0 = no pain, 10 = worst pain). The higher the score, the worse the pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative patient reported pain score on the visual analog scale</measure>
    <time_frame>Day 4</time_frame>
    <description>The visual analog scale (VAS) is a validated, subjective measure for pain. Scores range from 0-10 (0 = no pain, 10 = worst pain). The higher the score, the worse the pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative patient reported pain score on the visual analog scale</measure>
    <time_frame>Day 7</time_frame>
    <description>The visual analog scale (VAS) is a validated, subjective measure for pain. Scores range from 0-10 (0 = no pain, 10 = worst pain). The higher the score, the worse the pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Tibial Tubercle Osteotomy</condition>
  <arm_group>
    <arm_group_label>TTO + IV TXA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TTO, no IV TXA</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid (TXA)</intervention_name>
    <description>Patients will be given 1 gram of intravenous tranexamic acid (TXA) before tourniquet inflation and 1 gram of IV TXA before closure of the incision.</description>
    <arm_group_label>TTO + IV TXA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing TTO&#xD;
&#xD;
          -  Age 18-60&#xD;
&#xD;
          -  Willing and able to provide consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects,&#xD;
             dementia, etc.)&#xD;
&#xD;
          -  Younger than 18 years of age&#xD;
&#xD;
          -  Older than 60 years of age&#xD;
&#xD;
          -  Any patient considered a vulnerable subject&#xD;
&#xD;
          -  Have bleeding or clotting disorder&#xD;
&#xD;
          -  Preoperative anticoagulation therapy&#xD;
&#xD;
          -  Abnormal coagulation profile&#xD;
&#xD;
          -  Renal disorder or insufficiency&#xD;
&#xD;
          -  Sickle cell disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Alaia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tibial Tubercle Osteotomy</keyword>
  <keyword>Tranexamic Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemarthrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

